Floatz Rating
C38/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
23Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01119599CT.gov RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Meningioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| RG 4733 (this asset) | National Cancer Institute (NCI) | P1 | C · 38 |
| Nivestim | St. Jude Children's Research Hospital | P1 | CC |
| Trametinib | St. Jude Children's Research Hospital | P1 | CC |
| Therapeutic Allogeneic Lymphocytes | City of Hope Medical Center | P1 | CC |
| Sonidegib | St. Jude Children's Research Hospital | P1 | CC |
| Ribociclib | St. Jude Children's Research Hospital | P1 | CC |
| Onc 206 | Jazz Pharmaceuticals | P1 | CC |
| Gadobenate Dimeglumine | University of Southern California | N/A | D |
| Gadobutrol | University of Southern California | N/A | D |
Other indications for RG 4733
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P2 | CCC · 51 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 51 |
| Brain Neoplasm | — | P2 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. RG 4733 in Anaplastic Meningioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rg-4733-anaplastic-meningioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →